Genmab AS (GMAB) Stock Analysis

Genmab AS (GMAB) is a publicly traded company in the HEALTHCARE sector. It trades at $23.85, carries a market capitalization of $15.62B, a price-to-earnings ratio of 19.28. This page summarizes the public market data, fundamentals, and frequently asked questions for GMAB, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $23.85
• Market Cap: $15.62B
• P/E Ratio: 19.28
• EPS: $1.32
• 52-Week High: $35.43
• 52-Week Low: $20.23

Market Sentiment

Genmab AS currently has a Bullish sentiment score of 0.21.

About Genmab AS

Genmab AS is a prominent biotechnology company based in Copenhagen, Denmark, renowned for its innovative development of specialized antibody therapeutics aimed at treating cancer and other critical illnesses. The company boasts a strong pipeline supported by its proprietary technologies and strategic collaborations, driving advancements in next-generation therapies. With a steadfast commitment to improving patient outcomes through targeted immunotherapies, Genmab is well-positioned to capital...

GNG Research Analysis

GNG Research scores Genmab AS (GMAB) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for GMAB.

Frequently Asked Questions

Does GMAB pay dividends?

Genmab AS (GMAB) does not currently pay a regular dividend.

What is GMAB's P/E ratio?

Genmab AS has a price-to-earnings (P/E) ratio of 19.28.

What is GMAB's market cap?

Genmab AS (GMAB) has a market capitalization of $15.62B with a current stock price of $23.85.